Genetic polymorphism on type 2 receptor of angiotensin II, modifies cardiovascular risk and systemic inflammation in hypertensive males

American Journal of Hypertension

Volumn 23, Issue 3, 2010, Pages 237-242

  Tousoulis, Dimitris ^a   Koumallos, Nikolaos ^a   Antoniades, Charalambos ^a   Antonopoulos, Alexios S ^a   Bakogiannis, Constantinos ^a   Milliou, Antigoni ^a   Marinou, Kyriakoula ^a   Kallikazarou, Eleftheria ^a   Stefanadi, Elli ^a   Mentzikof, Dimitris ^b   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Amalia Fleming Hospital   (Greece)

Author keywords

Atherosclerosis; Blood pressure; Cardiovascular risk; Genetics; Hypertension; Inflammation

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GREECE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 2; RISK;

EID: 76749167528     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.233     Document Type: Article

References (25)

1. Tousoulis D, Antoniades C, Koumallos N, Stefanadis C. Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev 2006; 17:225-233.
2. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89:3A-9A; discussion 10A.
3. Sármán B, Skoumal R, Leskinen H, Rysä J, Ilves M, Soini Y, Tuukkanen J, Pikkarainen S, Lakó-Futó Z, Sármán B, Papp L, deChâtel R, Tóth M, Ruskoaho H, Szokodi I. Nuclear factor-kappaB signaling contributes to severe, but not moderate, angiotensin II-induced left ventricular remodeling. J Hypertens 2007; 25:1927-1939.
4. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007; 93:1001-1007.
5. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42:905-910.
6. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198:22-28.
7. Palmas W, Ma S, Psaty B, Goff DC Jr, Darwin C, Barr RG. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens 2007; 20:233-241.
8. Jin JJ, Nakura J, Wu Z, Yamamoto M, Abe M, Chen Y, Tabara Y, Yamamoto Y, Igase M, Bo X, Kohara K, Miki T. Association of angiotensin II type 2 receptor gene variant with hypertension. Hypertens Res 2003; 26:547-552. (Pubitemid 36974997)
9. Katsuya T, Higaki J, Ogihara T. [Gene loci and polymorphisms of angiotensin II receptor]. Nippon Rinsho 1999; 57:1020-1027.
10. Martin MM, Elton TS. The sequence and genomic organization of the human type 2 angiotensin II receptor. Biochem Biophys Res Commun 1995; 209:554-562.
11. Schmieder RE, Erdmann J, Delles C, Jacobi J, Fleck E, Hilgers K, Regitz-Zagrosek V. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 2001; 37:175-182.
12. Herrmann SM, Nicaud V, Schmidt-Petersen K, Pfeifer J, Erdmann J, McDonagh T, Dargie HJ, Paul M, Regitz-Zagrosek V. Angiotensin II type 2 receptor gene polymorphism and cardiovascular phenotypes: the GLAECO and GLAOLD studies. Eur J Heart Fail 2002; 4:707-712.
13. Kuznetsova T, Staessen JA, Thijs L, Kunath C, Olszanecka A, Ryabikov A, Tikhonoff V, Stolarz K, Bianchi G, Casiglia E, Fagard R, Brand-Herrmann SM, Kawecka-Jaszcz K, Malyutina S, Nikitin Y, Brand E; European Project On Genes in Hypertension (EPOGH) Investigators. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 2004; 110:2644-2650.
14. Erdmann J, Guse M, Kallisch H, Fleck E, Regitz-Zagrosek V. Novel intronic polymorphism (+1675G/A) in the human angiotensin II subtype 2 receptor gene. Hum Mutat 2000; 15:487.
15. Tousoulis D, Antoniades C, Koumallos N, Marinou K, Stefanadi E, Latsios G, Stefanadis C. Novel therapies targeting vascular endothelium. Endothelium 2006; 13:411-421.
16. Brili S, Tousoulis D, Antoniades C, Vasiliadou C, Karali M, Papageorgiou N, Ioakeimidis N, Marinou K, Stefanadi E, Stefanadis C. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. J Am Coll Cardiol 2008; 51:742-749.
17. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535-1542.
18. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343:1139-1147.
19. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon C P, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31:1460-1465. (Pubitemid 28273285)
20. Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. JAMA 2001; 285:581-587.
21. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103:1718-1720.
22. De Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000; 36:423-426.
23. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100:713-716. (Pubitemid 29383640)
24. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-1342.
25. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51:1157-1165.